|
22.11.2017 08:00:18
|
Immunicum AB: Invitation to Investor Events
Press release
November 22, 2017
Invitation to Investor Events
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events.
Aktiespararna Stora Aktiedagen in Gothenburg
Date: Monday, November 27, 2017
Presentation Time: 10:10-10:40 CET
Location: Svenska Mässan, Mässans Gata 8, Gothenburg
Please register to attend at https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg.
Immunicum Investor Event in Stockholm
Date: Thursday, November 30, 2017
Presentation Time: 18:00-19:00 CET
Location: United Spaces, Waterfront Building, Floor 2, Klarabergsviadukten 63, Stockholm
After the presentation, there is an opportunity to enjoy drinks and refreshments. Please register to attend by emailing info@immunicum.com no later than Tuesday, November 28, 2017.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor relations, sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com
Investor and Media Relations EU/US
Gretchen Schweitzer
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
about Immunicum AB (PUBL)Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Immunicum ABmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Immunicum ABmehr Analysen
Aktien in diesem Artikel
| Immunicum AB | 0,51 | 6,07% |
|
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.